United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $416.35, for a total transaction of $9,367,875.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Michael Benkowitz also recently made the following trade(s):
- On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00.
- On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total transaction of $1,961,050.00.
- On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The shares were sold at an average price of $397.41, for a total transaction of $4,520,538.75.
- On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $434.06 on Wednesday. The stock has a market capitalization of $19.58 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 6.32 and a beta of 0.62. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $438.26. The stock has a fifty day moving average of $334.71 and a 200-day moving average of $312.23.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's revenue was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.85 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have commented on the stock. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Jefferies Financial Group increased their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley cut their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $438.85.
Read Our Latest Analysis on UTHR
Institutional Investors Weigh In On United Therapeutics
A number of large investors have recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. SVB Wealth LLC acquired a new stake in United Therapeutics in the first quarter valued at approximately $32,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
